Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how gut microbiota dysbiosis contributes to Parkinson's disease, focusing on the gene NMNAT2 in a 6-hydroxydopamine (6-OHDA) rat model of the disease.
How was it studied?
Shotgun metagenome data from Parkinson's patients and healthy controls, plus KEGG and GEO microarray datasets, identified NMNAT2 as a downregulated NAD+ pathway gene. Researchers then tested fecal microbiota transplantation (FMT) and NMNAT2 overexpression or knockdown in 6-OHDA-lesioned rats.
What did they find?
Gut microbiota diversity, abundance, and functional composition differed significantly between Parkinson's patients and healthy individuals, with dysbiosis linked to a suppressed NAD+ anabolic pathway. NMNAT2 was reduced in brain tissue of both Parkinson's patients and lesioned rats; FMT or NMNAT2 overexpression restored motor performance (rotation, movement, rod latency) and normalized oxidative stress markers (MDA, GSH, SOD, GSH-Px), while NMNAT2 knockdown reversed FMT's benefits.
Why it matters
The findings suggest gut dysbiosis drives Parkinson's-like neurobehavioral deficits partly through suppressing NMNAT2, and that restoring gut microbiota or this gene could be a therapeutic strategy worth further study.